MX2019010554A - Pirimidopirimidinonas utiles como inhibidores de la quinasa wee-1. - Google Patents

Pirimidopirimidinonas utiles como inhibidores de la quinasa wee-1.

Info

Publication number
MX2019010554A
MX2019010554A MX2019010554A MX2019010554A MX2019010554A MX 2019010554 A MX2019010554 A MX 2019010554A MX 2019010554 A MX2019010554 A MX 2019010554A MX 2019010554 A MX2019010554 A MX 2019010554A MX 2019010554 A MX2019010554 A MX 2019010554A
Authority
MX
Mexico
Prior art keywords
wee
useful
pyrimidopyrimidinones
kinase inhibitors
compound
Prior art date
Application number
MX2019010554A
Other languages
English (en)
Inventor
Miel Hugues
Burkamp Frank
o'dowd Colin
Hewitt Peter
Wilkinson Andrew
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Publication of MX2019010554A publication Critical patent/MX2019010554A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un compuesto que es útil como un inhibidor de la actividad de la quinasa Wee-1. La presente invención también se refiere a composiciones farmacéuticas que comprenden este compuesto y a métodos para usar este compuesto en el tratamiento del cáncer y métodos para tratar el cáncer.
MX2019010554A 2017-03-10 2018-03-12 Pirimidopirimidinonas utiles como inhibidores de la quinasa wee-1. MX2019010554A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1703881.1A GB201703881D0 (en) 2017-03-10 2017-03-10 Pharmaceutical compounds
PCT/GB2018/050620 WO2018162932A1 (en) 2017-03-10 2018-03-12 Pyrimidopyrimidinones useful as wee-1 kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2019010554A true MX2019010554A (es) 2019-12-16

Family

ID=58605309

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010554A MX2019010554A (es) 2017-03-10 2018-03-12 Pirimidopirimidinonas utiles como inhibidores de la quinasa wee-1.

Country Status (30)

Country Link
US (2) US11208413B2 (es)
EP (1) EP3592745B1 (es)
JP (1) JP7244430B2 (es)
KR (1) KR102605546B1 (es)
CN (1) CN110603256B (es)
AU (1) AU2018231671B2 (es)
BR (1) BR112019018753A2 (es)
CA (1) CA3055874A1 (es)
CL (1) CL2019002557A1 (es)
CY (1) CY1124613T1 (es)
DK (1) DK3592745T3 (es)
EA (1) EA201992137A1 (es)
ES (1) ES2895365T3 (es)
GB (1) GB201703881D0 (es)
HR (1) HRP20211652T1 (es)
HU (1) HUE056220T2 (es)
IL (1) IL269063B (es)
LT (1) LT3592745T (es)
MA (1) MA47736B1 (es)
MX (1) MX2019010554A (es)
MY (1) MY195580A (es)
PH (1) PH12019502049A1 (es)
PL (1) PL3592745T3 (es)
PT (1) PT3592745T (es)
RS (1) RS62464B1 (es)
SA (1) SA519410093B1 (es)
SG (1) SG11201908114UA (es)
SI (1) SI3592745T1 (es)
UA (1) UA125093C2 (es)
WO (1) WO2018162932A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3078945A1 (en) 2017-10-09 2019-04-18 Nuvation Bo Inc. Heterocyclic compounds and uses thereof
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
CA3136492A1 (en) 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020210377A1 (en) * 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
US20220168313A1 (en) * 2019-04-09 2022-06-02 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
CA3237756A1 (en) * 2021-11-09 2023-05-19 Hangzhou Glubio Pharmaceutical Co., Ltd. Wee1 protein kinase degradation agent and use thereof
TW202337469A (zh) * 2022-03-07 2023-10-01 瑞士商德彪製藥國際公司 治療小細胞肺癌之方法
WO2023217201A2 (zh) * 2022-05-10 2023-11-16 杭州德睿智药科技有限公司 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
CA2745959A1 (en) * 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
EP2817308B1 (en) 2012-02-23 2016-09-07 AbbVie Inc. Pyridopyrimidinone inhibitors of kinases
GB201306610D0 (en) 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
PL3592745T3 (pl) 2022-01-03
ES2895365T3 (es) 2022-02-21
US20210128560A1 (en) 2021-05-06
IL269063B (en) 2022-04-01
PT3592745T (pt) 2021-10-20
EA201992137A1 (ru) 2020-02-05
KR102605546B1 (ko) 2023-11-22
UA125093C2 (uk) 2022-01-05
CN110603256B (zh) 2022-10-28
PH12019502049A1 (en) 2020-06-29
AU2018231671A1 (en) 2019-09-26
CL2019002557A1 (es) 2019-12-27
HUE056220T2 (hu) 2022-02-28
BR112019018753A2 (pt) 2020-04-07
MA47736A (fr) 2021-04-21
CY1124613T1 (el) 2022-07-22
SG11201908114UA (en) 2019-10-30
CN110603256A (zh) 2019-12-20
JP7244430B2 (ja) 2023-03-22
EP3592745A1 (en) 2020-01-15
MY195580A (en) 2023-02-02
US11208413B2 (en) 2021-12-28
EP3592745B1 (en) 2021-07-28
SA519410093B1 (ar) 2022-07-16
JP2020510040A (ja) 2020-04-02
HRP20211652T1 (hr) 2022-02-04
LT3592745T (lt) 2021-11-10
CA3055874A1 (en) 2018-09-13
SI3592745T1 (sl) 2021-12-31
US20220194947A1 (en) 2022-06-23
MA47736B1 (fr) 2021-10-29
WO2018162932A1 (en) 2018-09-13
AU2018231671B2 (en) 2022-03-24
DK3592745T3 (da) 2021-10-18
IL269063A (en) 2019-11-28
GB201703881D0 (en) 2017-04-26
KR20190128673A (ko) 2019-11-18
RS62464B1 (sr) 2021-11-30

Similar Documents

Publication Publication Date Title
ZA202007007B (en) Mcl-1 inhibitors
PH12019502049A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
MX2023005804A (es) Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
PH12020550857A1 (en) Polycyclic compounds as allosteric shp2 inhibitors
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
MX2022005216A (es) Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7).
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2023004037A (es) Compuestos biciclicos como inhibidores alostericos de shp2.
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
MX2016007801A (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
MX2019008696A (es) Compuestos de piridina como inhibidores de shp2 alostericos.
PH12016501546A1 (en) Cyclopropylamines as lsd1 inhibitors
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
EP4252851A3 (en) Ezh2 inhibitors for treating lymphoma
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
PH12020500072A1 (en) Heterocyclic inhibitors of atr kinase
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
MX2022001019A (es) Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38).
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
MX2019001011A (es) Compuestos farmaceuticos.
MX2020000367A (es) Inhibidores de rad51.
EA031679B9 (ru) Производные тетрагидрохинолина в качестве ингибиторов бромодомена
ZA201901367B (en) Inhibition of olig2 activity
TW202417457A (zh) Mcl-1抑制劑